| Autor: |
Ali Ihsan Yagoglu, Oguzhan Sıtkı Dizdar, Selahattin Erdem, Berkan Akcakaya, Ali Ihsan Gunal |
| Jazyk: |
Spanish; Castilian |
| Rok vydání: |
2020 |
| Předmět: |
|
| Zdroj: |
Nefrología, Vol 40, Iss 6, Pp 664-671 (2020) |
| Druh dokumentu: |
article |
| ISSN: |
0211-6995 |
| DOI: |
10.1016/j.nefro.2020.04.023 |
| Popis: |
Background: Linagliptin does not require dose adjustment in diabetes mellitus patients with chronic kidney disease (CKD). But, renal effects of linagliptin are not clear. Our aim was to examine the effect of linagliptin on renal disease progression in only insulin dependent type 2 diabetes mellitus (DM) patients with CKD. Methods: Stage 3–4 CKD patients were randomized into 2 groups in this prospective randomized controlled study. In the first group, linagliptin 5 mg was added in addition to the background insulin therapy. In the second group, patients continued their insulin therapy. Patients were followed up at 3-month intervals for one year. Results: The study population consisted of 164 patients (90 patients in linagliptin group, 74 patients in other group) with a mean age of 67.5 ± 8.8 years. eGFR significantly increased in linagliptin group (p = 0.033), but decreased in other group (p = 0.003). No significant change was observed in total insulin dose in linagliptin group (p = 0.111), but in other group, total insulin dose significantly increased (p |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
